ABSTRACT
OBJETIVO: Avaliar a massa ventricular esquerda em pacientes com insuficiência cardíaca, as correlações com outras variáveis clínicas e com o prognóstico. MÉTODOS: Foram estudados 587 pacientes com idades entre 13,8 anos e 68,9 anos, 461 (78,5 por cento) homens e 126 (21,5 por cento) mulheres. A massa ventricular esquerda foi estimada com o uso do ecocardiograma no modo M e indexada pela altura. RESULTADOS: O índice da massa ventricular esquerda variou de 35,3 g/m a 333,5 g/m e aumentou conforme a idade. O índice da massa ventricular esquerda foi maior nos homens (média 175,7 g/m) do que nas mulheres (média 165,7 g/m). O índice da massa ventricular esquerda foi maior nos portadores de cardiomiopatia hipertensiva (média 188,1 g/m), de cardiomiopatia dilatada idiopática (média 177,7 g/m) e de cardiomiopatias de outras etiologias (média 175,1 g/m) do que nos portadores de cardiomiopatia chagásica (média 164,3 g/m) e isquêmica (média 162 g/m). O índice da massa ventricular esquerda de portadores de insuficiência cardíaca demonstrou associação com a idade, o sexo, a etiologia e o diâmetro do átrio esquerdo. A correlação com a fração de ejeção do ventrículo esquerdo foi negativa - o aumento do índice da massa ventricular esquerda associou-se à redução da fração de ejeção. O risco relativo de óbito foi 1,22 para cada acréscimo de 50 g/m no índice da massa ventricular esquerda. CONCLUSÕES: A estimação da massa ventricular esquerda pode contribuir para a avaliação prognóstica de portadores de insuficiência cardíaca.
Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Heart Failure , Hypertrophy, Left Ventricular/diagnosis , Age Factors , Body Weights and Measures , Echocardiography , Epidemiologic Methods , Heart Ventricles , Hypertrophy, Left Ventricular/mortality , Hypertrophy, Left Ventricular/physiopathology , Prognosis , Sex FactorsABSTRACT
OBJECTIVE: To assess the effects of carvedilol in patients with idiopathic dilated cardiomyopathy. METHODS: In a double-blind randomized placebo-controlled study, 30 patients (7 women) with functional class II and III heart failure were assessed. Their ages ranged from 28 to 66 years (mean of 43ñ9 years), and their left ventricular ejection fraction varied from 8 per cnet to 35 per cent. Carvedilol was added to the usual therapy of 20 patients; placebo was added to the usual therapy of 10 patients. The initial dose of carvedilol was 12.5 mg, which was increased weekly until it reached 75 mg/day, according to the patient's tolerance. Clinical assessment, electrocardiogram, echocardiogram, and radionuclide ventriculography were performed in the pretreatment phase, being repeated after 2 and 6 months of medication use. RESULTS: A reduction in heart rate (p=0.016) as well as an increase in left ventricular shortening fraction (p=0.02) and in left ventricular ejection fraction (p=0.017) occurred in the group using carvedilol as compared with that using placebo. CONCLUSION: Carvedilol added to the usual therapy for heart failure resulted in better heart function.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Adrenergic beta-Antagonists/pharmacology , Carbazoles/pharmacology , Cardiac Output, Low/drug therapy , Cardiomyopathy, Dilated/drug therapy , Heart Rate/drug effects , Stroke Volume/drug effects , Adrenergic beta-Antagonists/administration & dosage , Adrenergic beta-Antagonists/therapeutic use , Carbazoles/administration & dosage , Carbazoles/therapeutic use , Cardiac Output, Low/etiology , Cardiomyopathy, Dilated/complications , Double-Blind Method , Heart Ventricles/drug effects , Norepinephrine/bloodABSTRACT
PURPOSE--To evaluate patient selection for heart transplantation or dynamic cardiomyoplasty. METHODS--We evaluated 380 patients from April 1991 to July 1993. The ages ranged between 16 and 68 (mean 43.5 +/- 11.46) years, 303 (79.7 per cent) were male. The diagnoses were dilated cardiomyopathy in 163 (42.9 per cent), Chagas' cardiomyopathy in 70 (18.4 per cent), ischemic heart disease in 61 (16.1 per cent), hypertensive heart disease in 40 (10.5 per cent), valvular heart disease in 23 (6.1 per cent), alcoholic cardiomyopathy in 12(3.2 per cent), peripartum cardiomyopathy in 5 (1.3 per cent) and myocarditis of unknown etiology in 5 (1.3 per cent). RESULTS--The indication of heart transplantation was eventually done in 55 (14.4 per cent), and 19 (5 per cent) were submitted to transplantation. Dynamic cardiomyoplasty was indicated in 9 (2.3 per cent) patients and was performed in 8 (2.1 per cent). In 30 (7.8 per cent) patients there were clinical contraindications for transplantation. Conventional surgical treatment was indicated for 12 (3.1 per cent) patients: myocardial revascularization and/or ventricular aneurismectomy in 5, surgical treatment of valvular heart disease in 6 and of atrial fibrillation in 1. Socioeconomic limitations precluded transplantation in 43 (11.3 per cent) and psychic limitations hindered transplantation in 23 (6.0 per cent) patients. Refusal of procedure by the patient occurred in 10 (2.6 per cent) cases. Improvement of the symptoms occurred in 69 (18.1 per cent) patients. CONCLUSION--A small percentage of patients are eligible and are eventually submitted to heart transplantation or dynamic cardiomyoplasty. New strategies may be delineated during follow up, as deferring transplantation or conventional surgical treatment of ischemic or valvular heart disease. Sociopsychic evaluation is an important step in the care of the patients